Hedera Dx
Epalinges
About Hedera Dx
With the use of Hedera Dx's liquid biopsy solution, hospital labs will be able to conduct clinically useful liquid biopsies on their own. This will greatly simplify tumor profiling. It is difficult to accomplish IVD compliance, privacy infrastructure, and validation, and even if these challenges are overcome, the current software workflows are inefficient to use and lack key capabilities. Hedera Dx was established on July 1, 2021 in Epalinges, Vaud.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $31.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2025)
- Website: hederadx.com
Industries & Categories
Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/hedera-dx-126380 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.